1. Academic Validation
  2. Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity

Toxicological Properties of 7-Methylguanine, and Preliminary Data on its Anticancer Activity

  • Front Pharmacol. 2022 Jul 6:13:842316. doi: 10.3389/fphar.2022.842316.
Kirill Kirsanov 1 2 Timur Fetisov 1 Elena Antoshina 1 Lubov Trukhanova 1 Tatiana Gor'kova 1 Olga Vlasova 1 Irina Khitrovo 1 Ekaterina Lesovaya 1 3 Nataliya Kulbachevskaya 1 Tatiana Shcherbakova 4 Gennady Belitsky 1 Marianna Yakubovskaya 1 Vytas Švedas 4 5 Dmitry Nilov 4
Affiliations

Affiliations

  • 1 Blokhin Cancer Research Center, Moscow, Russia.
  • 2 Peoples' Friendship University of Russia, Moscow, Russia.
  • 3 Pavlov Ryazan State Medical University, Ryazan, Russia.
  • 4 Belozersky Institute of Physicochemical Biology, Lomonosov Moscow State University, Moscow, Russia.
  • 5 Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
Abstract

7-Methylguanine (7-MG) competitively inhibits the DNA repair Enzyme poly(ADP-ribose) polymerase (PARP) and RNA-modifying Enzyme tRNA-guanine transglycosylase (TGT) and represents a potential Anticancer drug candidate. Furthermore, as a natural compound, it could escape the serious side effects characteristic for approved synthetic PARP inhibitors. Here we present a comprehensive study of toxicological and carcinogenic properties of 7-MG. It was demonstrated that 7-MG does not induce mutations or structural chromosomal abnormalities, and has no blastomogenic activity. A treatment regimen with 7-MG has been established in mice (50 mg/kg per os, 3 times per week), exerting no adverse effects or changes in morphology. Preliminary data on the 7-MG Anticancer activity obtained on transplantable tumor models support our conclusions that 7-MG can become a promising new component of chemotherapy.

Keywords

7-Methylguanine; cancer; carcinogenicity; inhibitor; toxicity.

Figures
Products